Clinical trials: Acute Granulocytic Leukemia
Relapsed/Refractory AML
The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)
The purpose of the study is to investigate the pharmacokinetics (PK) and cardiac properties of elacytarabine in patients with relapsed or refractory Acute Myeloid Leukaemia (AML).
- Trial name
- NCT01258816
- Testing
- Elacytarabine for infusion
- Where
- 6 sites in Spain, United Kingdom
- Volunteers
- 43 people
- Sponsor
- Clavis Pharma
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
An open-label study available to all eligible participants from Study B1371019 and participants originating from Study B1371012 continuing on study intervention with azacitidine with or without glasdegib.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
- Trial name
- NCT04842604
- Testing
- Glasdegib, Azacitidine
- Where
- 18 sites in Austria, Canada and 9 more
- Volunteers
- 14 people
- Sponsor
- Pfizer
Acute Myeloid Leukemia (AML)
A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation
Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well Venetoclax works to treat AML in adult participants who are ineligible for…
- Trial name
- INNOVATE (NCT04253314)
- Where
- 10 sites in Russia
- Volunteers
- 51 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia With Gene Mutations
Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib
An expanded access program (EAP): Allows doctors to give medicine to patients, Before it is approved by health authorities. This EAP is for: Quizartinib Patients with FLT3-ITD mutated AML, AML that has come back, or Is resistant…
- Trial name
- NCT03746912
- Testing
- Quizartinib Dihydrochloride
- Sponsor
- Daiichi Sankyo
Acute Myeloid Leukemia
Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML
This study compared treatment groups of patients treated with vosaroxin and cytarabine versus patients treated with placebo and cytarabine.
- Trial name
- VALOR (NCT01191801)
- Testing
- vosaroxin + cytarabine
- Where
- 124 sites in United States, Australia and 13 more
- Volunteers
- 711 people
- Sponsor
- Sunesis Pharmaceuticals
Acute Leukemias, Acute Myeloid Leukemia
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2Ds) of JNJ-75276617 in combination with a conventional chemotherapy backbone in pediatric and young adult participants with relapsed/refractory acute…
- Conditions
- Acute Leukemias, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Leukemia of Ambiguous Lineage
- Trial name
- NCT05521087
- Testing
- JNJ-75276617, Fludarabine, Cytarabine
- Sponsor
- Janssen Research & Development, LLC
Acute Myeloid Leukaemia, Chronic Myeloid Leukaemia
WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study
WT1 TCR gene therapy is a new treatment for acute myeloid leukaemia and chronic myeloid leukaemia. Patient's white blood cells (T cells) are modified to specifically fight the leukaemia cells by transferring a gene into the T…
- Trial name
- NCT01621724
- Testing
- WT1 TCR-transduced T cells
- Where
- 2 sites in United Kingdom
- Volunteers
- 7 people
- Sponsor
- Cell Medica Ltd
Acute Myeloid Leukemia
TL-895 and KRT-232 Study in Acute Myeloid Leukemia
This study evaluates TL-895, a potent, orally available and highly selective irreversible tyrosine kinase inhibitor combined with navtemadlin (KRT-232), a novel oral small molecule inhibitor of MDM2 for the treatment of adults…
- Trial name
- NCT04669067
- Testing
- TL-895, KRT-232
- Where
- 35 sites in United States, Australia and 6 more
- Volunteers
- 18 people
- Sponsor
- Telios Pharma, Inc.
Acute Myeloid Leukemia, Stem Cell Transplantation
Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
This study is a Phase 2 multicenter study with a Safety Lead-in evaluating safety and efficacy of MT-401 administration to patients with AML, who have received their first allogeneic HSCT.
- Trial name
- ARTEMIS (NCT04511130)
- Testing
- MT-401
- Where
- 18 sites in United States
- Volunteers
- 92 people
- Sponsor
- Marker Therapeutics, Inc.
Acute Myelogenous Leukemia (AML), Multiple Myeloma (MM)
Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer
The study is designed to evaluate safety, immunogenicity, and preliminary anti-tumor activity of a multi-peptide immunotherapy (BB-MPI-03) at three peptide+adjuvant dose levels.
- Conditions
- Acute Myelogenous Leukemia (AML), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Smoldering Multiple Myeloma (sMM)
- Trial name
- BBMPI03 (NCT02240537)
- Testing
- Sargramostim, BB-MPI-03, Montanide
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Benovus Bio, Inc.
Acute Myelogenous Leukemia
Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia
The purpose of this study is to evaluate clinical and laboratory safety associated with the administration of GVAX leukemia vaccine and to determine the feasibility of generation of GVAX leukemia vaccine in subjects with acute…
- Trial name
- NCT00116467
- Testing
- GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing)
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- Cell Genesys
Hematologic Malignancies, Acute Myeloid Leukemia
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
This study is a Phase 1, non-randomized, open-label/Phase 2 randomized, blinded study of ProTmune (ex vivo programmed mobilized peripheral blood cells) versus non-programmed mobilized peripheral blood cells for allogeneic…
- Conditions
- Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT02743351
- Testing
- ProTmune, Control Arm
- Where
- 15 sites in United States
- Volunteers
- 96 people
- Sponsor
- Fate Therapeutics
Relapsed/Refractory Acute Myeloid Leukemia
UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Main research purpose： Evaluate the safety and tolerance of UTAA06 injection in the treatment of patients with relapsed/refractory acute myeloid leukemia.
- Trial name
- NCT05731219
- Testing
- B7-H3 target, CAR gene modified gdT cell injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Leukemias, Acute Myeloid Leukemia (AML)
Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia
This study is designed to determine the safety, maximum tolerated dose,dose limiting toxicity of Terameprocol(EM-1421)and determine the pharmacokinetics (clearance from the blood)of Terameprocol(EM-1421)given as intravenous…
- Conditions
- Leukemias, Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Adult T Cell Leukemia (ATL)
- Trial name
- NCT00664677
- Testing
- Terameprocol (EM-1421)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Erimos Pharmaceuticals
Leukemia, Myelocytic, Acute
Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission
The study will compare the efficacy of the 2 treatments in intermediate and high-risk APL patients in achieving first hematological complete remission and molecular remission.
- Trial name
- NCT00962767
- Testing
- gemtuzumab ozogamicin, ATRA plus 6-MP and MTX
- Volunteers
- 168 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Study of BGB-11417 in Participants With Myeloid Malignancies
The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- NCT04771130
- Testing
- BGB-11417, Azacitidine, Posaconazole
- Where
- 47 sites in United States, Australia and 8 more
- Volunteers
- 260 people
- Sponsor
- BeOne Medicines
Acute Myeloid Leukemia
Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
The objective of this study was to assess the safety and tolerability, including the maximum tolerated dose, of gilteritinib in participants with relapsed or treatment-refractory acute myeloid leukemia (AML).
- Trial name
- NCT02014558
- Testing
- Gilteritinib, Voriconazole, Midazolam
- Where
- 26 sites in United States, Germany and 1 more
- Volunteers
- 265 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Leukaemia
First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome
Primary Objective: Dose escalation: To determine the maximum tolerated dose (MTD) of SAR440234 administered as a single agent in participants with relapsed or refractory acute myeloid leukemia (R/R AML), high risk myelodysplastic…
- Trial name
- NCT03594955
- Testing
- SAR440234
- Where
- 4 sites in United States, France
- Volunteers
- 7 people
- Sponsor
- Sanofi
Acute Myelogenous Leukemia, Diffuse Large B-Cell Leukemia
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
The purpose of this study is to assess the safety and tolerability of BMS-936564 (MDX-1338) in relapsed Acute myelogenous leukemia (AML) and other selected B-cell cancers and to determine the maximum tolerated dose (MTD) of the…
- Conditions
- Acute Myelogenous Leukemia, Diffuse Large B-Cell Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma
- Trial name
- NCT01120457
- Testing
- BMS-936564 (Anti-CXCR4)
- Where
- 11 sites in United States
- Volunteers
- 96 people
- Sponsor
- Bristol-Myers Squibb
Acute Myeloid Leukemia, Primary Myelofibrosis
A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia
This multicenter, open-label, phase 1 study designed to evaluate safety and tolerability of multi-kinase inhibitor LNK01002 in patients with primary myelofibrosis (PMF), or MF due to polycythemia vera (PV-MF), or essential…
- Conditions
- Acute Myeloid Leukemia, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- NCT04896112
- Testing
- LNK01002
- Where
- 2 sites in United States
- Sponsor
- Lynk Pharmaceuticals Co., Ltd